1990
DOI: 10.1111/j.1365-2710.1990.tb00361.x
|View full text |Cite
|
Sign up to set email alerts
|

Therapeutic Progress–review Xxxvii: Methotrexate–an Immunomodulator With Expanding Indications

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

1996
1996
2015
2015

Publication Types

Select...
2
2

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(1 citation statement)
references
References 31 publications
0
1
0
Order By: Relevance
“…Methotrexate is a competitive inhibitor of dihydrofolate reductase, preventing DNA synthesis and purine production [564]. Methotrexate therapy decreases levels of many of the proinflammatory cytokines found to be elevated in patients with inflammatory bowel disease, such as IL-1 [565], TNF, IFN-γ [566], and others.…”
Section: Methotrexatementioning
confidence: 99%
“…Methotrexate is a competitive inhibitor of dihydrofolate reductase, preventing DNA synthesis and purine production [564]. Methotrexate therapy decreases levels of many of the proinflammatory cytokines found to be elevated in patients with inflammatory bowel disease, such as IL-1 [565], TNF, IFN-γ [566], and others.…”
Section: Methotrexatementioning
confidence: 99%